Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v95.1.72.001k26_72_77PMID 10607687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

  1999cited by this paper
• Parametric likelihoods for multiple non-fatal competing risks and death.

  1998cited by this paper
• Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.

  1997cited by this paper
• Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.

  1997cited by this paper
• A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

  1996cited by this paper
• Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

  1994cited by this paper
• Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.

  1993cited by this paper
• Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

  1992cited by this paper
• Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

  1990cited by this paper
• A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.

  1987cited by this paper
• Factors related to length of complete remission in adult acute leukemia

  1980cited by this paper
• The effect of chemotherapy on acute leukemia in the human.

  1961cited by this paper

• Treatment outcomes and prognostic factors in children diagnosed with acute myeloid leukaemia in Uganda

  2025cites this paper
• Z-residual diagnostic tool for assessing covariate functional form in shared frailty models

  2024cites this paper
• Bayesian phase II adaptive randomization by jointly modeling efficacy and toxicity as time-to-event outcomes

  2024cites this paper
• Time independent factors that predict relapse in adults with acute myeloid leukemia

  2024cites this paper
• Z-residual diagnostics for detecting misspecification of the functional form of covariates for shared frailty models

  2023cites this paper
• Idarubicin versus Doxorubicin in Acute Myeloid Leukemia: A Parallel Randomized Trial with Pharmacoeconomic Analysis

  2023cites this paper
• Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission

  2022cites this paper
• Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy

  2022cites this paper
• Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy.

  2022cites this paper
• Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia

  2021cites this paper
• Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

  2021cites this paper
• Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy

  2021cites this paper
• Factors Influencing the Prognosis of Acute Myeloid Leukemia

  2021cites this paper
• IA方案和HAD方案诱导治疗FLT3-ITD突变阳性急性髓系白血病疗效比较

  2019cites this paper
• Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.

  2019cites this paper
• The impact of response kinetics for multiple myeloma in the era of novel agents.

  2019cites this paper
• Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases

  2018cites this paper
• Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

  2018cites this paper
• Clinical value of the quantitation of average daily platelet increase during the recovery period in childhood acute lymphoblastic leukaemia

  2018cites this paper
• Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

  2017cites this paper
• CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.

  2017cites this paper
• The Heme Oxygenase System in Hematological Malignancies

  2017cites this paper
• Acute myeloid leukemia: 2016 Update on risk‐stratification and management

  2016cites this paper
• Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?

  2016cites this paper
• Die Bedeutung physiologischer B-Vorläufer-Zellen (Haematogones) nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leukämie und myelodysplastischen Syndromen

  2016cites this paper
• Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate‐risk karyotype in first complete remission

  2015cites this paper
• 急性髓系白血病诱导缓解所需疗程与预后的关系

  2015cites this paper
• Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

  2015cites this paper
• Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy

  2015cites this paper
• Two‐stage adaptive randomization for delayed response in clinical trials

  2014cites this paper
• Acute myeloid leukemia: 2014 Update on risk‐stratification and management

  2014cites this paper
• Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

  2013cites this paper
• for acute myeloid leukemia predicts superior relapse-free survival Early peripheral blood blast clearance during induction chemotherapy

  2013cites this paper
• Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia

  2013cites this paper
• high clinical value has acute lymphoblastic leukemias: early immunophenotypic evaluation Minimal residual disease in adolescent (older than 14 years) and adult

  2013cites this paper
• Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia

  2013cites this paper
• Acute Myeloid Leukemia with Normal Cytogenetics

  2012cites this paper
• Novel Therapeutics for Chemotherapy-Resistant Acute Myeloid Leukaemia

  2012cites this paper
• Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model.

  2012cites this paper
• Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia

  2012cites this paper
• A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy

  2011cites this paper
• Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.

  2011cites this paper
• Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

  2011cites this paper
• What is the optimal induction strategy for older patients?

  2011cites this paper
• Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.

  2010cites this paper
• Biomarkers and surrogate end points—the challenge of statistical validation

  2010cites this paper
• Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis

  2010influential citation
• Inference for two‐stage adaptive treatment strategies using mixture distributions

  2010cites this paper
• Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes

  2009cites this paper
• Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia in the Adult

  2008cites this paper
• COCO-2: a model to assess the economic impact of an accident

  2008cites this paper
• Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

  2008cites this paper
• CXCR4 is a prognostic marker in acute myelogenous leukemia.

  2007cites this paper
• Overexpression of CXCR4 predicts adverse overall and event‐free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype

  2007cites this paper
• Pre-emptive antifungal therapy in neutropenic onco-hematology patients 2007

  2007cites this paper
• Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.

  2007cites this paper
• The challenge of the older patient [Abstract]

  2006cites this paper
• CXCR 4 is a prognostic marker in Acute Myelogenous Leukemia

  2006cites this paper
• Evaluation of complete disease remission in acute myeloid leukemia

  2006cites this paper
• Pronostic et traitement des leucémies aiguës myéloblastiques

  2006cites this paper
• A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases

  2006cites this paper
• Acute myeloid leukaemia.

  2006cites this paper
• Satellite Symposia and Meet-the-Professor Sessions

  2006cites this paper
• Autotransplantation versus HLA‐matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research

  2006cites this paper
• Prognostic factors in acute myeloid leukemia

  2005cites this paper
• Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

  2005cites this paper
• Monitoring of minimal residual disease in acute myeloid leukemia Monitorisierung minimaler Resterkrankung bei akuter myeloischer Leukämie

  2005cites this paper
• Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure

  2005cites this paper
• A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

  2004cites this paper
• FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia

  2004cites this paper
• Hematopoietic Recovery Following Induction Therapy of Acute Leukemias: Prognostic Implications and a New Look at the Definition of Remission

  2004cites this paper
• Bone Marrow Microvessel Density and it's Prognostic Significance in AML

  2004cites this paper
• Allogeneic and Autologous Stem Cell Transplantation for Acute Leukemia and Myelodysplasia in the Adult

  2004cites this paper
• The therapy of relapsed acute leukaemia in adults.

  2004cites this paper
• Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

  2004cites this paper
• Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

  2003cites this paper
• Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes

  2003cites this paper
• Monitoring of acute myeloid leukemia by flow cytometry

  2003cites this paper
• Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

  2003cites this paper
• Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia

  2003cites this paper
• A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

  2003influential citation
• Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.

  2003cites this paper
• Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

  2003cites this paper
• Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

  2003cites this paper
• Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia

  2003cites this paper
• Clinical Observations, Interventions, and Therapeutic Trials

  2002cites this paper
• Club Español de Citología Hematológica: el linfoblasto en el contexto de la leucemia linfoblástica aguda

  2002cites this paper
• Allogeneic Stem Cell Transplantation

  2002cites this paper
• Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission

  2002cites this paper
• Treatment of acute myeloid leukemia: state-of-the-art and future directions.

  2002cites this paper
• Treatment of acute myelogenous leukemia.

  2002influential citation
• Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors

  2002cites this paper
• Modeling Spatial Variation in Leukemia Survival Data

  2002cites this paper
• Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival

  2001cites this paper
• Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

  2001cites this paper
• Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia

  2001cites this paper
• The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.

  2001cites this paper
• Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

  2001cites this paper
• Prognostic factors in acute myelogenous leukemia

  2001cites this paper
• Verbesserung der Prognose bei Kindern mit AML: Ergebnisse der Studie AML-BFM 931

  2001cites this paper